Integrated Filing — IndAS

General information about company
Scrip Code	543245
NSE Symbol	GLAND
MSEI Symbol	NOTLISTED
ISIN	INE068V01023
Name of company	GLAND PHARMA LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	20-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	06-May-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Pharmaceuticals
Start date and time of board meeting	20-May-2025   15:00:00
End date and time of board meeting	20-May-2025   16:15:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	14249090000	56165040000
	Other income	440290000	2136080000
	Total income	14689380000	58301120000
2	Expenses
(a)	Cost of materials consumed	5875660000	19724790000
(b)	Purchases of stock-in-trade	30990000	144880000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-1027130000	1034140000
(d)	Employee benefit expense	3733670000	14015610000
(e)	Finance costs	74500000	420000000
(f)	Depreciation, depletion and amortisation expense	957610000	3778740000
(f)	Other Expenses
1	Power and fuel	526020000	1991540000
2	Other expenses	1634730000	6564840000
	Total other expenses	2160750000	8556380000
	Total expenses	11806050000	47674540000
3	Total profit before exceptional items and tax	2883330000	10626580000
4	Exceptional items	0	0
5	Total profit before tax	2883330000	10626580000
6	Tax expense
7	Current tax	1037370000	3719730000
8	Deferred tax	-19450000	-78410000
9	Total tax expenses	1017920000	3641320000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	1865410000	6985260000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	1865410000	6985260000
17	Other comprehensive income net of taxes	645260000	553870000
18	Total Comprehensive Income for the period	2510670000	7539130000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent	1865410000	6985260000
	Total profit or loss, attributable to non-controlling interests	0	0
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent	2510670000	7539130000
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
21	Details of equity share capital
	Paid-up equity share capital	164760000	164760000
	Face value of equity share capital	1	1
27	Details of debt securities
22	Reserves excluding revaluation reserve		91342650000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	11.32	42.4
	Diluted earnings (loss) per share from continuing operations	11.32	42.4
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	11.32	42.4
	Diluted earnings (loss) per share from continuing and discontinued operations	11.32	42.4
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results		1In terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 as amended the Listing requirements this Statement of Consolidated Financial Results for the quarter and year ended March 31 2025 Consolidated Financial Results of Gland Pharma Limited the Holding Company or the Company and its subsidiaries the Holding Company and its subsidiaries together referred to as the Group has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 20 2025 The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the year ended March 31 2025 and have issued an unmodified conclusion on the financial results for the quarter ended March 31 2025 n2The Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013 as amended and read with relevant rules thereunder and in terms of the Listing requirements n3The figures of the fourth quarter are the balancing figures between audited figures in respect of the full financial year and the published unaudited yeartodate figures up to the end of the third quarter of the relevant financial year which were subjected to a limited review nRefer the signed results uploaded for the complete notes

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Consolidated
	Assets
1	Non-current assets
	Property, plant and equipment	37505360000
	Capital work-in-progress	1505600000
	Investment property	0
	Goodwill	2482000000
	Other intangible assets	1057020000
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	0
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	0
	Total non-current financial assets	0
	Deferred tax assets (net)	520680000
	Other non-current assets	1349160000
	Total non-current assets	44419820000
2	Current assets
	Inventories	16852180000
	Current financial asset
	Current investments	0
	Trade receivables, current	15165330000
	Cash and cash equivalents	25562090000
	Bank balance other than cash and cash equivalents	0
	Loans, current	0
	Other current financial assets	4936200000
	Total current financial assets	45663620000
	Current tax assets (net)	0
	Other current assets	5313580000
	Total current assets	67829380000
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	112249200000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	164760000
	Other equity	91342650000
	Total equity attributable to owners of parent	91507410000
	Non controlling interest	0
	Total equity	91507410000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	776640000
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	294870000
	Total non-current financial liabilities	1071510000
	Provisions, non-current	1459910000
	Deferred tax liabilities (net)	2148070000
	Deferred government grants, Non-current	0
	Other non-current liabilities	413850000
	Total non-current liabilities	5093340000
	Current liabilities
	Current financial liabilities
	Borrowings, current	1915500000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	8204100000
	Total Trade payable	8204100000
	Other current financial liabilities	1260650000
	Total current financial liabilities	11380250000
	Other current liabilities	3022570000
	Provisions, current	508750000
	Current tax liabilities (Net)	736880000
	Deferred government grants, Current	0
	Total current liabilities	15648450000
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	20741790000
	Total equity and liabilites	112249200000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Unaudited	Audited
Nature of report standalone or consolidated		Consolidated	Consolidated
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Remeasurement of defined benefit plans	-8350000	-15800000
	Total Amount of items that will not be reclassified to profit and loss	-8350000	-15800000
2	Income tax relating to items that will not be reclassified to profit or loss	-1760000	-3830000
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss	-651850000	-565840000
5	Total Other comprehensive income	645260000	553870000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Unaudited
D	Nature of report standalone or consolidated			Consolidated
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			10626580000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			420000000
	Adjustments for decrease (increase) in inventories			-199180000
	Adjustments for decrease (increase) in trade receivables, current			422880000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-1642880000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			269030000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			1089520000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			3778740000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			0
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			100000
	Adjustments for dividend income			0
	Adjustments for interest income			0
	Adjustments for share-based payments			0
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			-2143930000
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			64470000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			2058750000
	Net cash flows from (used in) operations			12685330000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			3538030000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			9147300000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			3380000
	Purchase of property, plant and equipment			3845420000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			96240000
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			1564930000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			19420710000
	Net cash flows from (used in) investing activities	17047360000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			24880000
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			52830000
	Repayments of borrowings			628240000
	Payments of lease liabilities			183400000
	Dividends paid			3294880000
	Interest paid			305950000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			-4334760000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			21859900000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			131310000
	Net increase (decrease) in cash and cash equivalents			21991210000
	Cash and cash equivalents cash flow statement at beginning of period			3570880000
	Cash and cash equivalents cash flow statement at end of period			25562090000